Login to Your Account



'Sitting on a Potential Blockbuster'

Market 'Pain' Heed to Zalicus: Phase II Results Coming Soon

By Randy Osborne
Staff Writer

Friday, August 2, 2013
Zalicus Inc.'s shares gained ground the day after second-quarter earnings rolled out, as investors reawakened to the potential of Z160, the firm's Phase II oral, N-type calcium channel blocker for chronic pain.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription